Biogen Inc. Common Stock (BIIB)
Stock · NASDAQ · Health Care
$218.5as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 7,500
- Website
- www.biogen.com
Fundamentals
- 1-day range
- $217.53$219.7
- Market cap
- $30.48B
- P/E (trailing)
- 38.70
- P/E (forward)
- 13.20
- EPS (trailing)
- $5.64
- Dividend yield
- —
- Beta
- 0.16
- Avg. volume
- 1.15M
How Biogen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 6, 2026 · via SEC EDGAR / Finnhub
Forecasts
31 analyst ratings
Biogen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BIIBBiogen Inc. Common Stock$218.5▼ 1.35%Market cap $30.48BP/E 38.70$131.52$222.85
- BNTXBioNTech SE American Depositary Share$102.04▼ 8.40%Market cap $22.91BP/E —$79.52$124
- MRNAModerna Inc. Common Stock$137.93▼ 3.39%Market cap $21.50BP/E —$22.28$176.66
- RVMDRevolution Medicines Inc. Common Stock$207.89▼ 6.00%Market cap $42.05BP/E —$35.64$224.31
- NBIXNeurocrine Biosciences Inc. Common Stock$153.98▼ 1.24%Market cap $16.25BP/E 22.33$122.14$186.12
- HALOHalozyme Therapeutics Inc. Common Stock$105.33▼ 1.49%Market cap $10.17BP/E 27.63$61.23$109.66
- KYMRKymera Therapeutics Inc. Common Stock$118.08▼ 1.79%Market cap $8.75BP/E —$39.84$130.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BIIB Biogen Inc. Common Stock | $30.48B | 38.70 | $218.5 | ▼ 1.35% | $131.52$222.85 |
| BNTX BioNTech SE American Depositary Share | $22.91B | — | $102.04 | ▼ 8.40% | $79.52$124 |
| MRNA Moderna Inc. Common Stock | $21.50B | — | $137.93 | ▼ 3.39% | $22.28$176.66 |
| RVMD Revolution Medicines Inc. Common Stock | $42.05B | — | $207.89 | ▼ 6.00% | $35.64$224.31 |
| NBIX Neurocrine Biosciences Inc. Common Stock | $16.25B | 22.33 | $153.98 | ▼ 1.24% | $122.14$186.12 |
| HALO Halozyme Therapeutics Inc. Common Stock | $10.17B | 27.63 | $105.33 | ▼ 1.49% | $61.23$109.66 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $118.08 | ▼ 1.79% | $39.84$130.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 127.03M
- Total value held
- $22.35B
- Institutional holders
- 986
- Unknown15.97M
- Unknown14.76M
- Unknown12.81M
- Unknown9.54M
- Unknown7.17M
- Unknown4.34M
- Unknown2.96M
- Unknown2.17M
- Unknown1.92M
- Unknown1.75M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 29, 2026
Biogen Adopts Veeva Vault CRM Platform. Biogen has selected Veeva Systems' Vault CRM platform, according to recent company announcements highlighted in Veeva's earnings coverage. The move signals a shift in Biogen's customer relationship management infrastructure, though the financial terms of the deal were not disclosed. Separately, RBC Capital raised its price target on Biogen to $260 while maintaining an Outperform rating, citing continued confidence in the company. The stock is currently trading above the midpoint of its 52-week range of $131.52 to $222.85.